This company has been marked as potentially delisted and may not be actively trading. NASDAQ:XLRN Acceleron Pharma (XLRN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Acceleron Pharma Stock (NASDAQ:XLRN) Get Acceleron Pharma alerts:Sign Up Key Stats Today's Range$178.75▼$178.7550-Day Range$172.08▼$179.6852-Week Range$108.82▼$189.99VolumeN/AAverage Volume572,759 shsMarket Capitalization$10.93 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. Read More Receive XLRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XLRN Stock News HeadlinesAcceleron P Stock Price Today | NASDAQ: XLRN Live - Investing.comJune 28, 2025 | investing.comUK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma DealJanuary 2, 2025 | benzinga.comREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.October 14 at 2:00 AM | Paradigm Press (Ad)Acceleron Banks on Muons for Colder FusionDecember 6, 2024 | msn.comAcceleron Fusion has raised $15M to take a stab at colder fusion, filing revealsOctober 5, 2024 | techcrunch.comTAcceleron Fusion has raised $15M to take another stab at cold fusion, filing revealsOctober 1, 2024 | yahoo.comORBIMED CAPITAL GP II LLC's Net WorthFebruary 27, 2024 | benzinga.comXLRN Historical DataOctober 20, 2023 | investing.comSee More Headlines XLRN Stock Analysis - Frequently Asked Questions How were Acceleron Pharma's earnings last quarter? Acceleron Pharma Inc. (NASDAQ:XLRN) released its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($0.98) by $0.18. The business's revenue was up 51.6% on a year-over-year basis. What other stocks do shareholders of Acceleron Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acceleron Pharma investors own include Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA) and Vertex Pharmaceuticals (VRTX). Company Calendar Last Earnings11/04/2021Today10/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:XLRN CIK1280600 Webwww.acceleronpharma.com Phone(617) 649-9200Fax617-649-9988Employees312Year Founded2003Profitability EPS (Trailing Twelve Months)($4.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$166.03 million Net Margins-226.01% Pretax Margin-225.99% Return on Equity-32.11% Return on Assets-29.45% Debt Debt-to-Equity RatioN/A Current Ratio12.14 Quick Ratio12.14 Sales & Book Value Annual Sales$92.52 million Price / Sales118.15 Cash FlowN/A Price / Cash FlowN/A Book Value$11.74 per share Price / Book15.23Miscellaneous Outstanding Shares61,156,000Free Float60,116,000Market Cap$10.93 billion OptionableOptionable Beta0.13 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:XLRN) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acceleron Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acceleron Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
